Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Molecules and methods for modulating TMEM16A activities
US9045546B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9045546-B2 |
| Application number | US-201213690269-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2012 |
| Priority date | May 31, 2012 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody or antigen binding fragment thereof that specifically binds to the extracellular domain 3 (“ECD3”) of transmembrane protein 16A (“TMEM16A”), wherein said antibody or antigen binding fragment is internalized into the cell upon binding to the ECD3 and wherein the antibody or antigen binding fragment specifically binds to a peptide consisting of SEQ ID NO:4, and wherein the antibody or antigen binding fragment comprises a heavy chain CDR1 of SEQ ID N…
Assignees
Inventors
Classifications
- C07K16/30Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9045546B2 cover?
- The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
- Who is the assignee on this patent?
- Gaither Larry Alexander, Rothwell Christopher John, Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C07K16/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).